Karyopharm Therapeutics (KPTI) Other Accumulated Expenses (2012 - 2025)

Karyopharm Therapeutics has reported Other Accumulated Expenses for 14 years, with the latest figure at $1.6 million in Q4 2025.

• For the quarter ending Q4 2025, Other Accumulated Expenses fell 66.89% year-over-year to $1.6 million; the trailing twelve-month figure through Dec 2025 stood at $1.6 million (down 66.89% YoY), and the FY2025 full-year result was $1.6 million, down 66.89% from the prior year.
• Other Accumulated Expenses for Q4 2025 stood at $1.6 million, down from $1.8 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $7.6 million in Q4 2021, with the low at $524000.0 in Q2 2021.
• Historically, Other Accumulated Expenses has averaged $2.4 million across 5 years, with a median of $1.9 million in 2022.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses soared 255.92% — and 2023, when it tumbled 74.18%.
• Karyopharm Therapeutics' Other Accumulated Expenses stood at $7.6 million in 2021, then dropped by 15.96% to $6.4 million in 2022, then plunged by 74.18% to $1.7 million in 2023, then jumped by 188.51% to $4.8 million in 2024, then tumbled by 66.89% to $1.6 million in 2025.
• The last three Other Accumulated Expenses figures came in at $1.6 million (Q4 2025), $1.8 million (Q3 2025), and $1.6 million (Q2 2025), per Business Quant data.